Caris Life Sciences (NASDAQ: CAI) shares preliminary 2025 results, JPM materials

Rhea-AI Filing Summary

Caris Life Sciences, Inc. furnished an 8-K to report that it issued a press release with certain preliminary unaudited financial results for the quarter and full year ended December 31, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference for this results disclosure. The company also states that materials used for its presentation at the 2026 J.P. Morgan Healthcare Conference will be posted to its investor relations website. The information in this report, including the exhibit, is being furnished rather than filed, which limits its use in other securities law contexts.

0002019410FALSE00020194102026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________

FORM 8-K

_______________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

CARIS LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Texas

001-42706

85-2077369

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

750 W. John Carpenter Freeway Suite 800  Irving, TX						75039
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code: (866) 771-8946

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions :

☐						Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐						Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐						Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐						Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

CAI

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations and Financial Condition.

On January 12, 2026, Caris Life Sciences, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited financial results for the quarter and full year ended December 31, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein solely for purposes of this Item 2.02 disclosure.

Item 7.01    Regulation FD Disclosure.

On January 12, 2026, the Company will post materials that it will present at the 2026 J.P. Morgan Healthcare Conference to the Company's investor relations website at https://investor.carislifesciences.com. The website and presentation contents referenced herein are not incorporated into this Current Report on Form 8-K.

___________________________

The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release issued January 12, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2026
			CARIS LIFE SCIENCES, INC.
			By:			/s/ Luke Power
			Name:			Luke Power
			Title:			Senior Vice President, Chief Financial Officer and Chief Accounting Officer

FAQ

What did Caris Life Sciences (CAI) report in this 8-K?

Caris Life Sciences reported that it issued a press release containing certain preliminary unaudited financial results for the quarter and full year ended December 31, 2025, and furnished that release as Exhibit 99.1.

Which period do Caris Life Sciences’ preliminary results cover?

The preliminary unaudited financial results described by Caris Life Sciences cover the quarter and full year ended December 31, 2025.

Where can investors find Caris Life Sciences’ J.P. Morgan Healthcare Conference materials?

Caris Life Sciences will post the materials it presents at the 2026 J.P. Morgan Healthcare Conference on its investor relations website at https://investor.carislifesciences.com.

Is the Caris Life Sciences press release considered filed or furnished?

The company states that the information in this report, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.

What exhibit did Caris Life Sciences include with this 8-K?

Caris Life Sciences included Exhibit 99.1, a press release issued January 12, 2026, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the Caris Life Sciences 8-K?

The report was signed on behalf of Caris Life Sciences, Inc. by Luke Power, Senior Vice President, Chief Financial Officer and Chief Accounting Officer.